<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00221104</url>
  </required_header>
  <id_info>
    <org_study_id>J-STARS</org_study_id>
    <secondary_id>C000000207</secondary_id>
    <nct_id>NCT00221104</nct_id>
  </id_info>
  <brief_title>Japan Statin Treatment Against Recurrent Stroke (J-STARS)</brief_title>
  <official_title>Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <brief_summary>
    <textblock>
      Although hyperlipidemia is not always the risk factor of stroke, inhibition of
      3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of stroke
      in the patient with ischemic heart disease. The neuroprotective mechanism beyond cholesterol
      lowering should be expected to attenuate inflammation and atherosclerosis. The present study
      hypothesizes if pravastatin prevents recurrent stroke in the ischemic stroke patients with
      safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1, 2004</start_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Rate of Stroke and TIA</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incidence rate of patients with recurrent stroke of any type or transient ischemic attack (TIA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Atherothrombotic Infarction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incidence rate of patients with atherothrombotic infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Lacunar Infarction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incidence rate of patients with lacunar infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Cardioembolic Infarction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incidence rate of patients with cardioembolic infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of Intracranial Hemorrhage</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Incidence rate of patients with intracranial hemorrhage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1578</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient has no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <arm_group_label>Pravastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset

          -  Hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription of
             statin within previous 30 days

          -  Able to visit outpatient department

          -  Informed consent on the form.

        Exclusion Criteria:

          -  Ischemic stroke of other determined cause according to the TOAST classification

          -  Ischemic heart disease and necessary to use statin

          -  Hemorrhagic disorders

          -  Platelet count &lt;=100,000/ul within 3 months prior to study start

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)&gt;= 100IU/L within 3
             months prior to study start

          -  Serum creatinine &gt;=2.0mg/dl within 3 months prior to study start

          -  A scheduled operation

          -  The presence of malignant disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masayasu Matsumoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://jstars.umin.ne.jp</url>
    <description>Japan Statin Treatment Against Recurrent Stroke (J-STARS) only in Japanese</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>July 6, 2016</results_first_submitted>
  <results_first_submitted_qc>June 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2018</results_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>brain ischemia</keyword>
  <keyword>cerebrovascular accident</keyword>
  <keyword>statin</keyword>
  <keyword>hydroxymethylglutaryl-CoA reductase inhibitors</keyword>
  <keyword>cholesterol</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>hyperlipidemia</keyword>
  <keyword>multicenter studies</keyword>
  <keyword>prospective studies</keyword>
  <keyword>endpoint determination</keyword>
  <keyword>randomized controlled trials</keyword>
  <keyword>recurrence</keyword>
  <keyword>pravastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from March 2004 and February 2009 recruited at 123 clinical sites in Japan</recruitment_details>
      <pre_assignment_details>Participants were randomly assigned to the pravastatin group or the control with 1:1 allocation rate. The patient allocation was dynamically balanced with the stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence) between the two groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pravastatin Group</title>
          <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="793"/>
                <participants group_id="P2" count="785"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="710"/>
                <participants group_id="P2" count="709"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>intention to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Pravastatin</title>
          <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="793"/>
            <count group_id="B2" value="785"/>
            <count group_id="B3" value="1578"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="335"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="664"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="458"/>
                    <measurement group_id="B2" value="456"/>
                    <measurement group_id="B3" value="914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="248"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="491"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="545"/>
                    <measurement group_id="B2" value="542"/>
                    <measurement group_id="B3" value="1087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="793"/>
                    <measurement group_id="B2" value="785"/>
                    <measurement group_id="B3" value="1578"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="793"/>
                    <measurement group_id="B2" value="785"/>
                    <measurement group_id="B3" value="1578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ischemic stroke subtype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Atherothrombotic infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="206"/>
                    <measurement group_id="B3" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lacunar infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="502"/>
                    <measurement group_id="B2" value="504"/>
                    <measurement group_id="B3" value="1006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infarction of undetermined etiology</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High blood pressure</title>
          <description>The high blood pressure was defined ≥150/90 mmHg at baseline.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="485"/>
                    <measurement group_id="B2" value="476"/>
                    <measurement group_id="B3" value="961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="608"/>
                    <measurement group_id="B2" value="601"/>
                    <measurement group_id="B3" value="1209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate of Stroke and TIA</title>
        <description>Incidence rate of patients with recurrent stroke of any type or transient ischemic attack (TIA)</description>
        <time_frame>up to 5 years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Stroke and TIA</title>
          <description>Incidence rate of patients with recurrent stroke of any type or transient ischemic attack (TIA)</description>
          <population>intention to treat</population>
          <units>events /100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="793"/>
                <count group_id="O2" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" lower_limit="2.04" upper_limit="3.08"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.12" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the stratification factors at randomization: stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8234</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>log-rank test adjusted for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>the adjusted hazard ratio (HR) and the 95% confidence interval (CI) were calculated by the Cox proportional hazard model with for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Atherothrombotic Infarction</title>
        <description>Incidence rate of patients with atherothrombotic infarction</description>
        <time_frame>up to 5 years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group</title>
            <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
          </group>
          <group group_id="O2">
            <title>Pravastatin</title>
            <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Atherothrombotic Infarction</title>
          <description>Incidence rate of patients with atherothrombotic infarction</description>
          <population>intention to treat</population>
          <units>events /100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="785"/>
                <count group_id="O2" value="793"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.40" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.06" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the stratification factors at randomization: stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0047</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>log-rank test adjusted for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>The adjusted hazard ratio (HR) and the 95% confidence interval (CI) were calculated by the Cox proportional hazard model with for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Lacunar Infarction</title>
        <description>Incidence rate of patients with lacunar infarction</description>
        <time_frame>up to 5 years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Lacunar Infarction</title>
          <description>Incidence rate of patients with lacunar infarction</description>
          <population>intention to treat</population>
          <units>events /100 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="793"/>
                <count group_id="O2" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="0.90" upper_limit="1.63"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.69" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the stratification factors at randomization: stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3075</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>log-rank test adjusted for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
            <estimate_desc>The adjusted hazard ratio (HR) and the 95% confidence interval (CI) were calculated by the Cox proportional hazard model with for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Cardioembolic Infarction</title>
        <description>Incidence rate of patients with cardioembolic infarction</description>
        <time_frame>up to 5 years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Cardioembolic Infarction</title>
          <description>Incidence rate of patients with cardioembolic infarction</description>
          <population>intention to treat</population>
          <units>events /100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="793"/>
                <count group_id="O2" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.05" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.00" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the stratification factors at randomization: stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1986</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>log-rank test adjusted for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>9.14</ci_upper_limit>
            <estimate_desc>The adjusted hazard ratio (HR) and the 95% confidence interval (CI) were calculated by the Cox proportional hazard model with for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence Rate of Intracranial Hemorrhage</title>
        <description>Incidence rate of patients with intracranial hemorrhage</description>
        <time_frame>up to 5 years</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Intracranial Hemorrhage</title>
          <description>Incidence rate of patients with intracranial hemorrhage</description>
          <population>intention to treat</population>
          <units>events /100 person-years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="793"/>
                <count group_id="O2" value="785"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" lower_limit="0.12" upper_limit="0.46"/>
                    <measurement group_id="O2" value="0.31" lower_limit="0.14" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>the stratification factors at randomization: stroke subtype (atherothrombotic infarction vs. others), high blood pressure (≥150/90 mmHg vs. not), and diabetes mellitus (absence vs. presence)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9953</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>log-rank test adjusted for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>2.22</ci_upper_limit>
            <estimate_desc>The adjusted hazard ratio (HR) and the 95% confidence interval (CI) were calculated by the Cox proportional hazard model with for the stratification factors at randomization: stroke subtype, high blood pressure, and diabetes mellitus</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mean length of follow-up was 4.89 years.</time_frame>
      <desc>In the study AE form of clinical study CRF was not prepared. When serious adverse events (SAEs) in the study period were observed, SAEs were reported to principal investigator. AE/SAE were not observed at this study and those were spontanious reports from investigators. So the number at risk SAE (780) is not consistent with number participated (793). In regards to the Other AE, the meaning of number of participants at risk&quot;0&quot; here is because it were not monitored/ assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pravastatin Group</title>
          <description>The administration was initiated within 1 month after randomization, and the treatment was continued until final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 6·21 mmol/L (240 mg/dL) at routine clinical visits. Increase of pravastatin dose or addition of other non-statin drugs (such as ion exchange resin, eicosapentaenoic acid and ezetimibe) was allowed only when such reinforcements were insufficient. Even under such conditions, use of other statins (such as simvastatin and atorvastatin) was prohibited.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>The administration of any statin was prohibited, although use of other non-statin drugs was allowed when necessary.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second d</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorr</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrh</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Therapy responder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Encephalitis brain stem</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Infected epidermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Median nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase in</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate co</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Adrenocortical carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the duodenu</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gingival cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbala</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurologic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Spinal cord infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Cerebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary d</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Sleep apnea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Epiglottic cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Gastrostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hepatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Removal of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Laminaplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis migrans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="785"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="780"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="785"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Medical Statistics Division</name_or_title>
      <organization>Translational Research Informatics Center, Kobe, Hyogo</organization>
      <phone>+81-78-303-9108</phone>
      <email>kagimura@tri-kobe.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

